PLoS ONE · 2012 · 18 citations · 37 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyImmunology Of Infectious DiseasesTransplant ImmunologyCell-mediated ImmunityCytotoxic T Lymphocyte ResponsesAntiviral T Cell ResponsesCd4 Positive T Cell ResponsesCd4 Positive T CellsCd4+ T Helper Cell ResponsesCd8 Positive T Cell ResponsesDonor-recipient ImmunologyT-cell Immune ResponsesViral-specific Cytotoxic T Lymphocyte Responses
CMV status is an important risk factor in immune compromised patients. In hematopoeitic cell transplantations (HCT), both donor and recipient are tested routinely for CMV status by serological assays; however, one might argue that it might also be of relevance to examine CMV status by cellular (i.e., T lymphocyte) assays. Here, we have analyzed the CMV status of 100 healthy blood bank donors using both serology and cellular assays. About half (56%) were found to be CMV seropositive, and they all mounted strong CD8+ and/or moderate CD4+ T cell responses ex vivo against the immunodominant CMV protein, pp65. Of the 44 seronegative donors, only five (11%) mounted ex vivo T cell responses; surprisingly, 33 (75%) mounted strong CD4+ T cell responses after a brief in vitro peptide stimulation culture. This may have significant implications for the analysis and selection of HCT donors.
37
Elizabeth Walter, Philip D. Greenberg, M. Jean Gilbert et al. · New England Journal of Medicine · 1995 · 1.8K citations
Andrew Sylwester, Bridget L. Mitchell, John B. Edgar et al. · The Journal of Experimental Medicine · 2005 · 1.3K citations · Full text